SCHEMBL5882071

SCHEMBL5882071

Cc1[nH]c2ccc(C(=O)NS(=O)(=O)C=Cc3ccccc3)cc2c1Cc1ccc(Cl)cc1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.42
PTGS2 P35354 1/20 0.41
SNCA P37840 1/20 0.41
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.38
THRB P10828 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TP53 P04637 1/20 0.38
PTPN5 P54829 1/20 0.38
MCL1 Q07820 1/20 0.38
CNR1 P21554 3/20 0.37
TBXA2R P21731 1/20 0.37
PTGFR P43088 1/20 0.37
PTGER3 P43115 1/20 0.37
PTGER2 P43116 1/20 0.37
PTGIR P43119 1/20 0.37
PTGDR Q13258 1/20 0.37
KDM4E B2RXH2 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
HDAC1 Q13547 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5882069 1.00 MAPT (0.42) MAPTPTGS2SNCAALDH1A1LMNA
SCHEMBL5881740 0.93 SNCA (0.39) MAPTPTGS2SNCALMNATP53
SCHEMBL5881737 0.93 SNCA (0.39) MAPTPTGS2SNCALMNATP53
SCHEMBL5881987 0.91 MAPT (0.42) MAPTPTGS2SNCATP53PTPN5
SCHEMBL6135076 0.91 MAPT (0.41) MAPTPTGS2ALDH1A1LMNASMN1; SMN2
SCHEMBL6135073 0.91 MAPT (0.41) MAPTPTGS2ALDH1A1LMNASMN1; SMN2
SCHEMBL5881849 0.90 PTPN5 (0.48) MAPTSNCAPTPN5MCL1CNR1
SCHEMBL5881853 0.90 PTPN5 (0.48) MAPTSNCAPTPN5MCL1CNR1
SCHEMBL6318588 0.89 SCN5A (0.40) MAPTPTGS2SNCALMNATP53
SCHEMBL6319284 0.89 SCN5A (0.40) MAPTPTGS2SNCALMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7115647-B2 Method of inhibiting neoplastic cells with indole derivatives OSI PHARMACEUTICALS, INC. (US) 2006-10-03 US disclosed
US-20020143022-A1 Method of inhibiting neoplastic cells with indole derivatives OSI PHARMACEUTICALS, INC. 2002-10-03 US disclosed
US-6410584-B1 ANTICANCER AGENTS CELL PATHWAYS, INC. 2002-06-25 US disclosed
EP-1132087-A1 REMEDIES FOR POLYCYSTIC OVARY SYNDROME FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020143022-A1 Method of inhibiting neoplastic cells with indole derivatives IDO1, IDO2, INMT MAPT 4038/4885PTGS2 230/4885SNCA 930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.